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Staging by sentinel node (SN) biopsy is the standard procedure for
clinically node-negative breast cancer patients. Intra-operative
analysis of the SN allows immediate axillary lymph node (ALN)
dissection in SN positive patients, but a quick, reliable and repro-
ducible method is lacking. We tested the suitability of a quantita-
tive cytokeratin 19 (CK19) mRNA one step nucleic acid ampliﬁca-
tion (OSNA
#) technique (OSNA-CK19) for intra-operative SN
analysis. OSNA-CK19 involves a short manual sample prepara-
tion step and subsequent fully automated ampliﬁcation of CK19
mRNA based on reverse transcription loop-mediated isothermal
ampliﬁcation, with results available within 30–40 min. OSNA-
CK19 was compared to histological staining (Hematoxylin&Eosin
and CAM5.2 and CK19 immunostaining) of 346 frozen ALNs
from 32 breast cancer patients, using half of the lymph node for
each method. 267 samples were negative and 61 positive by both
methods. Three samples were histology positive and OSNA-CK19
negative. Fifteen samples were histology negative and OSNA-
CK19 positive, 11 of which had copy numbers close to the cut-off
level of OSNA-CK19. Seven of these 15 samples were RT-PCR
positive for epithelial markers and/or showed CK19 protein
expression by Western blot suggesting the presence of tumor
deposits in the lymph node part investigated by OSNA-CK19.
Concordance with histology was 94.8%, and 96.8% after exclusion
of the latter 7 discordant cases. Sensitivity was 95.3% and speciﬁc-
ity was 94.7% before and 97.1% after discordant case investiga-
tion. Our results indicate that OSNA-CK19 can potentially be use-
ful in an intra-operative clinical setting to detect SN tumor
involvement in breast cancer patients.
' 2008 Wiley-Liss, Inc.
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The negative status of the sentinel lymph node (SN) in clini-
cally lymph node-negative breast cancer patients is highly predic-
tive for the negative status of the remaining axillary lymph nodes
(ALN), and hence SN mapping has become a routine procedure
for surgical staging of breast cancer patients.
1–4 Rapid techniques,
which are used to identify tumor deposits such as touch imprint
preparations and cytological smears lack sufﬁcient sensitivity.
5,6
Consecutive frozen sections can also be done intra-operatively but
also show a suboptimal sensitivity of in between 70 and 90%.
7,8
Therefore, in many laboratories SN analysis is usually performed
postoperatively by staining consecutive step formalin-ﬁxed tissue
sections at 3–5 levels, depending on the size of the lymph node,
with Hematoxylin and Eosin (H&E) and a pan cytokeratin
marker.
9,10 However, this thorough assessment of formalin-ﬁxed
tissue is not applicable for intra-operative testing.
11 As a conse-
quence, the patient needs to be subjected to ALN dissection
(ALND) in a second surgery session, if the postoperative histolog-
ical examination of the SN turns out to be positive. Therefore,
there is a need for a rapid, highly sensitive and speciﬁc method,
which can be used for intra-operative assessment of the SN status.
Molecular approaches such as real-time PCR have been applied
for the detection of tumor deposits in lymph nodes of breast cancer
patients and indicated higher sensitivity than histological investi-
gations.
12–14 Results obtained with RT-PCR correlated with tradi-
tional predictors of prognosis
13
CK19 mRNA is a suitable marker for identifying breast cancer
deposits in lymph nodes because virtually all breast cancers
express this cytoskeleton protein.
15 Recently, a new semi-auto-
mated molecular method for rapid intra-operative diagnosis of
lymph node metastases in breast cancer patients has been devel-
oped using One step nucleic acid ampliﬁcation (OSNA). The
OSNA-CK19 assay (Sysmex, Kobe, Japan) is based on homogeni-
sation of lymph node samples followed by real-time ampliﬁcation
and quantitation of cytokeratin 19 (CK19) mRNA directly from
the lysate, with results available within 30 min for one SN and
40 min for 4 SNs. The quantitative molecular result is related to
the size of the metastases.
In recent studies performed in Japan OSNA-CK19 has been
found to be a potentially valuable intra-operative method for the
detection of lymph node metastases in patients with gastric,
16 col-
orectal,
17 and breast cancer.
18 To ﬁnd out whether this method has
also potential to be a good intra-operative alternative for a more
extensive postoperative histological work-up of SNs that is com-
mon in many European settings, we tested the performance of the
OSNA-CK19 method in comparison with the standard histological
method (staining step sections with H&E and pan cytokeratin
staining) in 346 ALN from 32 Dutch breast cancer patients under-
going ALND.
Material and Methods
Patients and source of lymph nodes
Three hundred and forty six fresh lymph nodes were obtained
from ALND specimens of 32 breast cancer patients undergoing
axillary dissection in the Medical Centre Alkmaar, Alkmaar, the
Netherlands, and the VU University medical center in Amsterdam
from June 2005 to July 2006. These included 14 patients that
underwent a SN procedure of which only non-SNs were analyzed
in our study. The remaining 18 patients did not undergo a SN pro-
cedure. Patients receiving neoadjuvant therapy were excluded
from the study. Patient characteristics are shown in Table I.
Patients were staged according to the TNM classiﬁcation.
19
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Lymph node samples were cut in 4 equal slices (a, b, c, d) with
a special cutting device.
18 Two of these slices (a&c) were snap-
frozen in liquid nitrogen and stored at 280C until OSNA analysis
was performed. The remaining 2 slices (b&d) were ﬁxed in 4%
buffered formaldehyde and embedded in a single parafﬁn block
for histological examination at 5 levels since this was the standard
in-house method for sentinel node investigation in both breast can-
cer and melanoma patients (Fig. 1).
20
In 346 lymph node samples concordance, sensitivity and speci-
ﬁcity were determined based on the comparison of these 2 meth-
ods. To investigate whether these ﬁgures might be inﬂuenced by a
sampling bias caused by limited investigation of the material the
histologic work-up was extended to all levels in the ﬁrst 120 histo-
logically negative lymph node samples. The same was done for
parafﬁn blocks of discordant cases. In addition, the homogenised
lymph node lysates of samples with discordant OSNA versus his-
tology results were subjected to quantitative reverse-transcriptase
polymerase chain reaction (QRT-PCR) and Western Blot analysis.
In case these investigations yielded a result compatible with a pos-
itive OSNA result these samples were excluded from the ﬁnal
analysis because of a strong indication for sampling bias.
Histological work-up
Lymph nodes were cut using special cutters depending on the
size. The blades of this device were 1 mm apart for lymph nodes
with a minor axis of 4–6 mm and 2 mm apart for lymph nodes
with a minor axis of 6–10 mm. Lymph nodes with a minor axis
larger than 10 mm were halved, and the resulting pieces were then
cut either with the 1 mm or 2 mm cutting device depending of the
size of the pieces. Of the slices b and d initially three 4-lm thick
sections were stained with H&E, CAM5.2 (Becton Dickinson,
Mountain View, CA) and an anti-CK19 antibody (code No.
M0888 and clone No RCK 108, Dako, Glostrup, Denmark),
respectively. If the initial sections were tumor positive no further
sections were cut. Otherwise, additional sections (n 5 3) at further
levels at an interval of 250 lm (usually 4) were cut and analyzed
(Fig. 2). Immunostaining was performed with an antibody against
cytokeratin 8 (CAM5.2) as well as CK19. Separate sections con-
taining nonneoplastic epithelial cells were included in each stain-
ing procedure and served as a positive control for both antibodies.
The size of a metastasis was determined by measuring its larg-
est diameter and categorized as isolated tumor cells (ITC: <0.2
mm), micrometastasis (tumor deposits larger than 0.2 mm but
smaller than 2.0 mm), or macrometastasis (tumor deposits equal to
or larger than 2.0 mm).
19 Microscopic evaluation was done by 2
pathologists (MV and MJ) without prior knowledge of the results
of the OSNA method. Histology was regarded positive if at least 1
micrometastasis or macrometastasis was detected in 1 of the sec-
tions. Lymph nodes containing isolated tumor cells were recorded
as lymph node negative and designated as N0(i1) according to
the 6th UICC TNM classiﬁcation.
21
One step nucleic acid ampliﬁcation assay for CK19 mRNA
In the OSNA method the lysate of a homogenised lymph node
was directly used for ampliﬁcation purposes without prior isola-
tion and puriﬁcation of RNA, as has been recently described in
detail.
18 Homogenisation was carried out with the homogenizing
reagent Lynorhag, pH 3.5, (Sysmex, Kobe, Japan) and subsequent
ampliﬁcation with the ready-to-use Lynoamp Kit (Sysmex, Kobe,
Japan) on the RD-100i (Sysmex, Kobe, Japan) according to the
manufacturer’s instruction. Ampliﬁcation was performed by
reverse transcription loop-mediated isothermal ampliﬁcation (RT-
LAMP) (2000),
22 as lately presented for CK19 mRNA.
18 Ampliﬁ-
cation products were detected by real-time monitoring of turbidity
changes caused by the increase of magnesium pyrophosphate con-
centration, a by-product of the ampliﬁcation reaction.
23 A total of
6 primers implied a high degree of speciﬁcity for the reaction and
exhibited no cross-reaction with CK19 pseudogenes a and b (Gen-
bank accession number M33101 and U85961). The primers for the
ampliﬁcation of CK19 mRNA were the same as described else-
TABLE I – CLINICOPATHOLOGICAL CHARACTERISTICS OF PATIENTS
Number of patients
Stage
00
I A/B 8
II A/B 15
III A/B/C 7
IV 2
Nodal status
pN0 14
pN1 10
pN2 6
pN3 2
Histopathological type
Invasive ductal carcinoma 30
Invasive lobular carcinoma 2
FIGURE 1 – Study design: Histology versus OSNA. 346 lymph node
samples were cut into 4 pieces. Slices ‘‘a’’ and ‘‘c’’ were subjected to
the OSNA method, slices ‘‘b’’ and ‘‘c’’ to histological work-up con-
sisting of 5 levels of H&E, CAM5.2 and CK19 staining. In 120 histo-
logically negative lymph node samples, as determined by the 5 level
method, the remainder of the block was completely cut into further
levels to assess speciﬁcity. 18 samples with differing results as
obtained by the 2 methods (discordant cases) were also cut into further
levels.
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18 The ampliﬁcation process for each sample took 16 min.
The processing and ampliﬁcation of 3 samples took 30–40 min.
To check the quality of mRNA in the lysates ampliﬁcation of
the mRNA of the housekeeping gene beta-actin was performed
using the following primers:
50-TGAAGGTAGTTTCGTGGATGCCTGAGGCACTCTTCC
AGC-30 (forward inner primer), 50-TGAAGTGTGACGTGGA
CATCCAGGGTACATGGTGGTGC-30 (reverse inner primer), 50-
TGGCAATGAGCGGTTCC-30 (forward outer primer),
50-TCCTTCTGCATCCTGTCG-30 (reverse outer primer),
50-ACAGGACTCCATGCCC-30 (loop forward primer) and 50-
TGTACGCCAACACAGTGC-30 (loop reverse primer).
The same reagent and ampliﬁcation conditions as described
elsewhere
18 were applied for both beta-actin and CK19 markers.
According to the manufacturer’s speciﬁcations (Sysmex), the
threshold level for the CK19 mRNA OSNA was set at 250 copies/
lL lysate on the basis of previous data obtained from a series of
normal lymph nodes.
18 Consequently, in case the CK19 mRNA
copy numbers, as expressed per lL of original lysate, were lower
than 250 copies/lL the result was designated as (2). Copy num-
bers between 250 and 5,000/lL were designated as (1), and copy
numbers higher than 5,000/lLa s( 11), as recommended by the
manufacturer. In terms of comparison to results obtained by histo-
pathology, negative (2) is consistent with negative histology or
presence of ITC, scored as pN0 and N0(i1), respectively,
19 (1)
most likely is associated with a micrometastasis, and (11) with a
macrometastasis as determined by basic data obtained for CK19
mRNA OSNA.
18
Quantitative reverse-transcriptase polymerase chain reaction
About 200 lL of the frozen lysate from discordant lymph node
cases were used for extraction of total RNA with the RNeasy Mini
Kit (QIAGEN, Valencia, CA). If the RNA concentration of the
eluate was > 50 ng/lL, the 260–280 nm absorbance ratio (A260/
A280) higher than 1.7, and the electrophoretic measurement on
agarose gels yielded 2 sharp ribosomal RNA bands, QRT-PCR on
the ABI Prism 7700 detector (Applied Biosystems, Foster City,
CA) was performed. In case one of these criteria was not met, the
RNA was considered to be of poor quality and the corresponding
samples were not subjected to QRT-PCR.
Puriﬁed RNA (2 lL) was subjected to one-step QRT-PCR with
QuantiTest SYBR Green (QIAGEN, Hilden, Germany) according
to the manufacturer’s instructions. Primers were designed by the
Primer Express Version 2.0 software (Applied Biosystems). QRT-
PCR was performed for CK19, SPDEF (SAM pointed domain
containing ETS transcription factor), FOXA1 (forkhead box A1)
and beta-actin with the QuantiTest SYBR Green (Invitrogen Corp,
San Diego, CA). The latter served as house-keeping gene for an
extra quality check of the RNA for RT-PCR purposes. The
sequences of RT-PCR primers for beta-actin ampliﬁcation were
50-CCACACTGTGCCCATCTACG-30 (forward) and 50-
AGGATCTTCATGAGGTAGTCAGTCAG-30 (reverse). Primer
sequences of the other markers were recently listed.
18
All QRT-PCR reactions were performed in duplicate. Cut-off
levels for CK19, SPDEF and FOXA1 were determined based on
results obtained from a series of lymph nodes from breast cancer
patients with and without undisputable metastases. Both cut-off
level and results from the sample runs were expressed in threshold
cycles (Ct). A Ct is deﬁned as the PCR cycle in which the ﬂuores-
cence exceeds a deﬁned baseline signal. Cut-off levels for CK19,
SPDEF and FOXA1 were deﬁned as the mean Ct 1 3 times the
standard deviation (SD) obtained from lymph nodes of pN0
patients. The cut-off levels used were Ct 24.0 for beta-actin, Ct
31.5 for CK19, Ct 31.6 for SPDEF and Ct 33.8 for FOXA1.
Western blot analysis
CK19 Western Blot analysis of the lysates from discordant
cases was performed as previously illustrated,
18 using A53-B/A2
(Santa Cruz Biotechnology) as the primary anti-CK19 antibody. A
standard curve for CK19 protein was established based on 4 cali-
brators with CK19 protein concentrations of 0.15, 0.075, 0.038
and 0.018 ng/lL, respectively (Biodesign, Saco, ME). CK19 pro-
tein concentrations of the samples were identiﬁed according to
this standard curve. A cut-off value for CK19 protein expression
of 0.13 ng/lL (mean 1 3 SDs), was determined based on the
CK19 protein expression levels of 37 histologically negative
lymph nodes of pN0 breast cancer patients. The results were
expressed as ng/lL of original lysate.
Results
OSNA-CK19 versus histology
In all lysates of the 346 lymph node samples beta-actin mRNA
expression was detected indicating the presence of RNA of
adequate quality to serve as a template for RT-LAMP.
Consequently, all 346 lymph node samples were investigated
by both the OSNA assay and histology. Two hundred and sixty
seven samples were negative and 61 samples positive by both
methods (Table II). In 3 of these 267 tumor negative concordant
cases, ITC were found by immunohistochemistry in only 1 section
of the tissue part examined by histology. There were 18 discordant
cases. In 15 of these samples a positive result was obtained by the
OSNA-CK19 method compared to a negative histology result. On
the other hand, OSNA-CK19 analysis revealed a negative result in
3 histologically positive cases. Thus the concordance rate, as
determined without incorporating any additional data from dis-
cordant case investigation, between the OSNA and histological
FIGURE 2 – Schematic represen-
tation of the histological work-up.
Both slices ‘‘b’’ and ‘‘d’’ of each
lymph node sample were embed-
ded into 1 parafﬁn block. Three
initial 4-lm thick sections were
stained with H&E, CAM5.2 and
CK19, respectively. Afterwards,
4 additional levels with 250-lm
skip space in between them were
prepared.
2564 VISSER ET AL.methods was 94.8%. By considering the histological procedures as
the gold standard the sensitivity of OSNA for detecting tumor
deposits was 95.3% and the speciﬁcity was 94.7%. To ﬁnd out to
what extent these ﬁgures might be inﬂuenced by a sampling bias
caused by limited investigation of the material the ﬁrst 120 histo-
logically negative lymph nodes, as determined by 5 level histol-
ogy, were cut into further levels at an interval of 250 lm until no
remnants remained. These included 5 lymph nodes showing a pos-
itive OSNA-CK19 result. In none of these samples metastatic
deposits were detected after extended analysis.
In 50 out of 53 cases with histologically detectable macrometa-
stases, the OSNA-CK19 assay of the adjacent slice showed a
(11) result, 2 cases revealed a (1) result, and 1 macrometastasis
was not detected in the adjacent lymph node slice used for OSNA-
CK19 (Table II). This macrometastasis (Table III, discordant case
no. 1) had a diameter of 2.78 mm. 4/11 micrometastases had (11)
results, 5/11 had (1) results and 2/11 revealed a (2) CK19 OSNA
result. One of these micrometastases (1.5 mm in diameter, dis-
cordant case no. 2) was located in level 2 and 3 of the correspond-
ing parafﬁn block but not in levels 1, 4 and 5. The other one (1
mm in diameter, discordant case no. 3) was detected only in level
2 but not in any other level.
Discordant case investigation
To investigate if discordant results between OSNA-CK19 and
histological examination resulted from a sampling bias such that
tumor deposits were found exclusively in either slices used for his-
tology, b&d, or slices used for OSNA, a&c, the homogenate of
‘‘a’’ and ‘‘c’’ slices of all these samples was further investigated by
QRT-PCR for mRNA markers indicative for epithelial cells
(CK19, SFDEF and FOXA1) as well as for CK19 protein by West-
ern Blotting, whenever possible (Table III). Moreover, in addition
to the 5 samples belonging to the ﬁrst 120 histologically negative
samples subjected to extended analysis, also parafﬁn blocks b&d
from the 10 remaining OSNA positive, histology negative samples
were further serially sectioned until no remnants remained, and
these sections were stained by H&E, CAM 5.2 and an anti-CK19
antibody. No tumor deposits were detected with these additional
histological analyses.
In 8 cases, only Western Blot analysis for CK19 protein could
be obtained because poor quality RNA did not allow QRT-PCR
(Table III). One (no. 2) of 3 histology positive/OSNA-CK19 nega-
tive samples (no. 1–3) could be analyzed by QRT-PCR and
yielded negative results for all 3 markers. In the lysates of samples
nos. 1 and 2, CK19 protein levels of 0.14 ng/lL and 0.17 ng/lL,
respectively, were slightly above the cut-off level suggesting the
presence of small tumor deposits. In 11 histologically negative
samples (no. 4–14) low CK19 mRNA copy numbers (250–750/
lL) were found with OSNA-CK19. Six of these could be further
analyzed by QRT-PCR,
6,7,9,11–13 whereas the remaining 5 samples
suffered from poor RNA quality. The same was true for 1 sample
(No. 18) with high CK19 mRNA copy number (Table III).
In summary, in 7 out of 18 discordant samples (no. 5, 7, 11, 12,
13, 15 and 16) sampling bias was suggested to be the reason for
TABLE III – ANALYSIS OF DISCORDANT CASES BY ADDITIONAL MARKERS INDICATIVE FOR EPITHELIAL CELLS
No. Histology RNA quality
QRT-PCR (threshold cycle)
Conclusion OSNA CK19 protein Beta-actin
2 CK19
3 SPDEF
4 FOXA1
5
Copies /lL 1/2 Ng/lL
1 1/2 Ct 1/2 Ct 1/2 Ct 1/2 Ct 1/2
1 1 ND 2 0.14 1 poor Could not be performed Still discordant
6
2 1 ND 2 0.17 1 OK 19.4 1 31.8 2 32.2 2 35.4 2 Still discordant
3 1 ND 2 0.09 2 poor Could not be performed Still discordant
4 2 270 1 0.06 2 poor Could not be performed Still discordant
5 2 330 1 0.13 1 poor Could not be performed Sampling bias
6 2 340 1 0.04 2 OK 18.9 1 33.7 2 32.5 2 34.6 2 Still discordant
7 2 400 1 0.20 1 OK 19.1 1 33.0 2 33.0 2 34.5 2 Sampling bias
8 2 420 1 0.09 2 poor Could not be performed Still discordant
9 2 520 1 0.05 2 OK 19.8 1 33.0 2 33.5 2 35.7 2 Still discordant
10 2 620 1 0.05 2 poor Could not be performed Still discordant
11 2 640 1 0.06 2 OK 17.8 1 32.3 2 32.1 2 33.8 1 Sampling bias
12 2 710 1 0.12 2 OK 19.3 1 30.8 1 32.5 2 34.6 2 Sampling bias
13 2 720 1 0.30 1 OK 18.2 1 28.7 1 30.3 1 32.9 1 Sampling bias
14 2 730 1 0.06 2 poor Could not be performed Still discordant
15 2 1400 1 0.16 1 OK 20.3 1 33.6 2 32.6 2 39.0 2 Sampling bias
16 2 2500 1 3.61 1 OK 19.4 1 25.4 1 25.3 1 25.6 1 Sampling bias
17 2 12000 11 0.12 2 OK 19.1 1 33.6 2 32.4 2 38.0 2 Still discordant
18 2 12000 11 0.06 2 poor Could not be performed Still discordant
ND, not detected; p, poor.
In two samples (6 and 9) no CK19 protein and no CK19, SDDEF and FOXA1 mRNA was detected. In 4 samples (4, 8, 10 and 14) QRT-PCR
could not be performed and Western blotting yielded negative results. Analysis of samples 11 and 12 gave only positive RT-PCR results
with FOXA1 and CK19, respectively, suggestive of very small tumour deposits in these samples. In samples 5 and 7 CK19 protein concentra-
tion above the cut-off level was detected but no (in sample 5) or negative (sample 7) QRT-PCR results. Sample no. 13 and 16 gave positive
results in Western Blot for CK19 and all 3 markers in QRT-PCR, strongly suggestive of the presence of tumor cells in the lysate. A positive
OSNA-CK19 result with high copy number was observed in 2 samples (17 and 18), with no metastases detected by histological methods. In
sample 15, CK19 protein was present. In samples 17 and 18 data obtained by Western blotting and RT-PCR were negative or could not be
performed, respectively.
1Cut-off level: 0.13 ng/lL, cut-off value as indicated in threshold cycles (Ct).–
2Beta-actin: 24.0.–
3CK19: 31.5.–
4SPDEF: 31.6.–
5FOXA1:
33.8.–
6Still discordant: 8 of these cases could not be investigated by RT-PCR due to poor RNA quality.
TABLE II – COMPARISON OF THE RESULTS OF OSNA-CK19 WITH HISTOLOGICAL EXAMINATION
Histological work-up: 5 levels
OSNA CK19 Macrometastases
N 5 53
Micrometastases
N 5 11
Isolated tumour
cells N 5 3
Negative
N 5 279
11 50 4 0 2
1 250 1 3
2 1 2 3 264
2565 INTRA-OPERATIVE OSNA ASSAY FOR LYMPH NODE METASTASESdiscordant data since at least 1 of the additional analyses results
was compatible with a positive OSNA-CK19 result (Table III). If
these 7 samples were excluded from the study because of suspi-
cion for sample allocation bias, sensitivity remained 95.3% (61/
64) but speciﬁcity and concordance rate increased to 97.1% (267/
275) and 96.8% (328/339), respectively.
Discussion
Since there is no fast method for high quality lymph node
assessment available, current histology-based SN protocols
require a second surgical procedure once the node is found to be
tumor positive.
24
In the present study a novel OSNA-CK19 method was com-
pared to immunohistological examination at 5 levels on 346 ALNs
of 32 breast cancer patients. OSNA-CK19 had a sensitivity of
95.3% and a concordance rate of 94.8%, when the results of fur-
ther discordant case analyses were not taken into consideration.
Of the 3 histologically positive samples that were negative in the
OSNA-CK19 assay, 2 were attributed to micrometastases and 1 to
a small macrometastasis with a diameter of 2.78 mm (Table III).
Without considering the results of discordant case investigation
the speciﬁcity of OSNA was 94.7%. For 7 of the 18 discordant
cases a sampling bias was likely to be the case on the basis of fur-
ther QRT-PCR and Western Blot data. If these samples were
excluded from the analysis the speciﬁcity and concordance rates
increased to 97.1 and 96.8%, respectively, without affecting the
sensitivity. Of 8 additional discordant cases that could not be ana-
lysed by QRT-PCR tissue allocation bias cannot be excluded and
therefore these cases are not necessarily false-positive in OSNA.
The reason that the RNA in the lysates of other discordant samples
was of insufﬁcient quality for further analysis most likely results
from the fact that the lymph node lysates were stored after the
OSNA run for a couple of months before discordant case investi-
gation was performed. In addition, the homogenisation buffer
used for the OSNA method is not the optimized homogenising so-
lution recommended by QIAGEN as part of their RNA puriﬁcation
protocol.
It should be noted that both slices a&c were completely ana-
lyzed by OSNA, whereas the 250-lm skip ribbons of slices b&d
used for histology were discarded. In this way more tissue is used
for the OSNA investigation and therefore a higher sensitivity of
the OSNA assay for tumor deposits as compared to histologic
work-up can be expected. The high sensitivity and speciﬁcity and
the short analysis time make OSNA-CK19 the method of choice
for rapid assessment of lymph node metastases in breast cancer
patients.
It should be noted that isolated tumor cells ( 0.2 mm) are not
detected by OSNA-CK19 and are classiﬁed as lymph node nega-
tive. Presently, lymph nodes containing ITC, as demonstrated by
histology are clinically considered as metastasis negative and des-
ignated as N0(i1) by TNM classiﬁcation.
19 Most ITC are found
by immunohistochemical staining only and not by H&E stain-
ing.
25 At the moment the clinical signiﬁcance of ITC in lymph
nodes of breast cancer patients is unknown, and currently there is
no consensus regarding ALND or further treatment in the presence
of ITC.
25,26
Several earlier studies described CK19 mRNA expression in
lymph nodes from patients without cancer, producing false posi-
tive results.
27–29 To prevent this, a CK19 mRNA cut-off level of
250 copies/lL lysate, as determined in a different study,
18 was
used in OSNA-CK19. By using this approach any illegitimate
CK19 mRNA background expression sometimes present in lymph
nodes will fall below the cut-off level of the method and will not
interfere with the detection of tumor deposits. Moreover, 6 pri-
mers were chosen in such a way that pseudogenes are not ampli-
ﬁed. In conclusion, the OSNA method based on CK19 mRNA as
described in our study is an attractive intra-operative tool for the
detection of lymph node metastases in breast cancer patients.
Since the whole lymph node can be investigated, sampling errors,
which are inherent to histological techniques, are prevented by
OSNA. Alternatively, a small part of the lymph node could be re-
served for other investigations. However, the larger the part of the
lymph node that is excluded from the OSNA analysis the higher
the chance that tumor deposits might be missed. Due to an auto-
mated pipetting procedure and ready-to-use reagent kit a high
degree of standardization and objectivity is achieved. Intra-opera-
tive use of OSNA may spare a patient from the discomfort and
complications of a second surgical intervention. Additional studies
including intra-operative OSNA analyses of sentinel lymph nodes
are currently underway.
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